COVID-19 preclinical drug development database
Name: Neill Liptrott
Email Address: firstname.lastname@example.org
Phone Number: 0151 795 7566
Our previous work has demonstrated that inhibition of inflammasome activation may prove beneficial in treating patients with severe immunological responses. We have recently published a strategy for the repurposing of existing drugs, for utility against SARS-CoV-2, based on their EC50 against the virus and their pharmacokinetic parameters. We now propose to utilise this strategy to determine the impact of these drugs on inflammasome inhibition. Following a literature search of the prioritised drugs, we have identified a number of options for inflammasome inhibition to be used clinically in COVID-19 patients and aligned this with known pharmacokinetic parameters. The purpose of the, proposed, work is to accurately determine the impact of these molecules on inflammasome activation in validated model systems (human immune cell lines), define their EC50s and as part of a strategy to repurpose existing drugs, with defined safety/tolerability profiles, and determine their clinical application as immune modulators in COVID-19 patients.